JNJ-39393406

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameJNJ-39393406
Drug Alias NameJNJ-39393406
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeuronal acetylcholine receptor protein alpha-7 subunit modulators
TargetsNeuronal acetylcholine receptor protein alpha-7 subunit
Therapy Area/IndicationsSchizophreniaCognition DisordersSmoking Cessation +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesRomania +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthUniversity Of PittsburghVirginia Commonwealth University +[6] 
Active IndicationsN/A
Inactive IndicationsSchizophreniaCognition DisordersSmoking Cessation +[5] 

Other Information

ATC CodeN/A
Related LinksN/A